Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.9.4763

Toll-like Receptor 5 Agonism Protects Mice from Radiation Pneumonitis and Pulmonary Fibrosis  

Wang, Zhi-Dong (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Qiao, Yu-Lei (College of Life Science, Hebei United University)
Tian, Xi-Feng (College of Life Science, Hebei United University)
Zhang, Xue-Qing (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Zhou, Shi-Xiang (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Liu, Hai-Xiang (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Chen, Ying (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.9, 2012 , pp. 4763-4767 More about this Journal
Abstract
Radiation pneumonitis and pulmonary fibrosis are the main complications with radiotherapy for thoracic neoplasms, directly limiting the efficient dose in clinical application and currently there are few medicines that effectively function as radioprotectants. However, a TLR5 agonist, CBLB502, was confirmed to have protective efficacy against hematopoietic and gastrointestinal radiation syndromes in mice and primates. This study points to a new direction for protection against thoracic radiation-induced pulmonary syndromes and skin injury by CBLB502. We utilized the TUNEL assay, pathological analysis and immunohistochemistry to obtain evidence thatCBLB502 could alleviate the occurrence of radiation pneumonitis and pulmonary fibrosis as well as radiation-induced skin injury. It may thus play a promising role in facilitating clinical radiotherapy of thoracic neoplasms.
Keywords
CBLB502; radiation pneumonitis; pulmonary fibrosis; thoracic radiotherapy;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Atkinson K, Vos B, Kang-Er Z, et al (1995).Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graftversus- host disease and survival after murine haematopoietic stem cell transplantation. Cytokines Mol Ther, 1, 47-55.
2 Brickey WJ, Neuringer IP, Walton W, et al (2012).MyD88 provides a protective role in long-term radiation-induced lung injury. Int J Radiat Biol, 88, 335-47.   DOI
3 Burdelya LG, Gleiberman AS, Toshkov I, et al (2012). Tolllike receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys, 83, 228-34.   DOI
4 Burdelya LG, Krivokrysenko VI, Tallant TC, et al (2008). An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 320, 226-30.   DOI
5 Dale DC (2002). Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs, 62, S1-15.
6 Delanian S, Baillet F, Huart J, et al (1994). Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase (clinical trial). Radiother Oncol, 32, 12-20.   DOI
7 Epperly MW, Sikora CA, DeFilippi SJ, et al (2002).Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane. Radiat Res, 157, 568-77.   DOI   ScienceOn
8 Krivokrysenko V, Shakhov A, Singh V, et al (2012). Identification of G-CSF and IL-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure. J Pharmacol Exp Ther, 343, 497-508.   DOI
9 Kuwano K, Hagimoto N, Kawasaki M, et al (1999). Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J ClinInvest, 104, 13-9
10 Mehta V (2005). Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys, 63, 5-24.   DOI   ScienceOn
11 Tallant T, Deb A, Kar N, et al (2004). Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells. BMCMicrobiol, 4, 33.
12 Vijay-Kumar M, Aitken JD, Sanders CJ, et al (2008).Flagellin treatment protects against chemicals, bacteria,viruses, and radiation. J Immunol, 180, 8280-5.   DOI
13 Wynn TA (2007). Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest, 117, 524-9.   DOI
14 Zhou SX, Li FS, Qiao YL, et al (2012). Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner. Asian Pac J Cancer Prev, 13, 2807-12.   DOI